RxDoctor Payments Data

Aaron Utterback

Podiatrist · Olympia, WANPI 1831599521

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.2% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Smith+Nephew at 46.9% of the total. Reporting peaked in 2019 at $572 and has fallen 55.7% since, to $253 in 2025.

$1,279in general payments, 2019–2025

Across 51 payments — averaging $25.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$600
  • Biowound Solutions, Inc.$311
  • Organogenesis Inc.$125
  • Medline Industries LP$78
  • Amgen$48
  • Osiris Therapeutics Inc.$41
  • plus $76 from 4 others

What the payments were for

  • Speaking & faculty fees$12510%
  • Food & beverage$1,15490%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Smith+Nephew26$600
Biowound Solutions, Inc.13$311
Organogenesis Inc.1$125
Medline Industries LP1$78
Amgen3$48
Osiris Therapeutics Inc.2$41
Merck2$32
Arthrosurface Incorporated1$19
Zimvie Inc.1$13
CPM Medical Consultants, LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,279 in reported general payments places this provider in the 60th percentile of 134 podiatrist providers in Washington.

See all podiatrist providers in Washington

Medicare billing

Part B allowed, 2024
$972,150
Medicare patients
430
Services billed
3,692

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin33$1,461
Ketoconazole18$938
Pregabalin12$929
Mupirocin37$623
Doxycycline Hyclate17$296
Methylprednisolone13$125

Paid to pharmacies, not to this prescriber.

Other podiatrist in Olympia

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →